Method Devolopment and Validation of Antineoplastic Drug in Solid Dosage form Using HPLC Method by Ali Ebraheem, Fadlallah Ebraheem
METHOD DEVOLOPMENT AND VALIDATION OF 
ANTINEOPLASTIC DRUG IN SOLID DOSAGE FORM 
USING HPLC METHOD 
 
A dissertation submitted to 
THE TAMILNADU Dr.M.G.R MEDICAL UNIVERSITY 
CHENNAI- 600 032. 
 
In partial fulfillment of the requirements for the award of Degree of 
MASTER OF PHARMACY 
IN 
PHARMACEUTICAL ANALYSIS  
Submitted  
 
BY 
ALI  EBRAHEEM FADLALLAH EBRAHEEM  
Reg.No.261330951 
Under the guidance of 
Prof.Dr.D.Babu Ananth, M.Pharm,Ph.D., 
 
 
 
           DEPARTMENT OF PHARMACEUTICAL ANALYSIS, 
EDAYATHANGUDY.G.S PILLAY COLLEGE OF PHARMACY 
NAGAPATTINAM-611002 
OCT  2015 
 METHOD DEVOLOPMENT AND VALIDATION OF 
ANTINEOPLASTIC DRUG IN SOLID DOSAGE FORM 
USING HPLC METHOD 
 
A dissertation submitted to 
THE TAMILNADU Dr.M.G.R MEDICAL UNIVERSITY 
CHENNAI- 600 032. 
 
In partial fulfillment of the requirements for the award of Degree of 
MASTER OF PHARMACY 
IN 
PHARMACEUTICAL ANALYSIS  
 
Submitted  
By 
 
Reg.No. 261330951 
 
 
 
      DEPARTMENT OF PHARMACEUTICAL ANALYSIS, 
EDAYATHANGUDY.G.S PILLAY COLLEGE OF PHARMACY 
NAGAPATTINAM-611002 
OCT 2015 
  
Prof.Dr.D.BabuAnanth,M.Pharm., Ph.D., 
Principal, 
Edayathangudy.G.S.Pillay College of Pharmacy, 
Nagapattinam – 611 002. 
 
                      CERTIFICATE 
 This is to certify that the dissertation entitled “METHOD 
DEVOLOPMENT AND VALIDATION OF ANTINEOPLASTIC 
DRUG IN SOLID DOSAGE FORM USING HPLC METHOD” 
submitted     by   Ali  Ebraheem Fadlallah Ebraheem (Reg No: 
261330951)in partial fulfillment for the award of degree of Master of 
Pharmacy to the Tamilnadu Dr. M.G.R Medical University, Chennai is an 
independent bonafide work of the candidate carried out under my 
guidance in Department of Pharmaceutical Analysis, 
Edayathangudy.G.S.Pillay College of Pharmacy, 
Nagapattinam.during the academic year 2014-2015. 
 
Place: Nagapattinam 
                                         Prof.Dr.D.BabuAnanth,M.Pharm., Ph.D., 
Date: 
 
 
 
                                  
                         ACKNOWLEDGEMENT 
  
 I would like to express profound gratitude to Jothimani Chevalier 
Thiru.G.S.Pillay, Chairman, E.G.S.Pillay College of Pharmacy, and 
Thiru.S.Paramesvaran, M.Com., FCCA.,Secretary, E.G.S.Pillay College 
of Pharmacy. 
 I express my sincere and deep sense of gratitude to my guide 
Prof.Dr.D.BabuAnanth, M.Pharm, Ph.D., Principal, Department of 
Pharmaceutical Analysis, Edayathangudy.G.S.Pillay College of 
Pharmacy,  for his invaluable and extreme support, encouragement, and 
co-operation throughout the course of my work. 
 I express my sincere gratitude to Prof. Dr.M.Murugan, M.Pharm., 
Ph.D.,Director cum Professor, Head, Department of Pharmaceutics. 
E.G.S.Pillay College of Pharmacy, for his encouragement throughout the 
course of my work. 
 I  wish  to  express  my  great  thanks  to Prof.K.Shahul Hameed 
Maraicar , M.Pharm., (Ph.D), Director  cum Professor , Department     of 
Pharmaceutics, E.G.S.Pillay College of Pharmacy, for his support and   
valuable guidance during my project work. 
 I would like to extend my thanks to  all the Teaching  Staff and 
Non Teaching Staff, who are all supported me for the successful 
completion of my project work.        
 Last but not least, I express my deep sense of gratitude to my 
parents, family members and friends for their constant valuable blessings 
and kindness. 
 
 
INDEX  
 
S.NO 
 
CONTENTS 
 
PAGE NO 
1 INTRODUCTION 1 
2 LITERATURE REVIEW 9 
3 DRUG PROFILE 12 
4 AIM & OBJECTIVE 19 
5 PLAN OF WORK 20 
6 MATERIALS & METHODS 22 
7 RESULTS & DISCUSSION 39 
8 SUMMARY 76 
9 CONCLUSION 78 
10 BIBLIOGRAPHY 79 
 
 
 
 
 
 
 
\ 
1 
 
 
 
1.0. INTRODUCTION  
 
 
1.1. The Importance Of Newer Analytical Method1  
 
Drug analysis entails identification, characterization and determination of 
drugs in mixtures such as dosage forms and biological fluids. The number of drugs 
acquainted into the market has been increasing at an alarming rate. These drugs 
may be either new entity in the market or partial structural modifications of the 
existing drug. Newer analytical methods are developed for these drugs or drug 
combinations of the following reasons: 
 
 The drug or drug combinations mayn‟t be official in any pharmacopoeia.  
 
 Exploring literature may not reveal an analytical method for the drug or its 
combinations.  
 
 Analytical methods may not be available for the drug combination due to 
the interference caused by excipients.  
 
 Analytical methods for the quantification of drug or drug combination from 
biological fluid may not be available or usable.  
 
 Analytical methods for a drug in combination with other drugs may not be 
available.  
 
 
On the other hand, the existing procedure may, 
 
 Require expensive instruments, the reagents, solvents etc. 
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 Involve any tedious extraction or separation steps, which may be quite time 
consuming.  
 
 Not be rapid, reliable or sensitive.  
 
 
The newly developed analytical methods2 find their importance in various fields 
like 
 
 Research institutions,  
 
 Quality control department in industries,  
 
 Approved testing laboratories,  
 
 Bio-pharmaceutics and Bio-equivalence studies,  
 
 Clinical pharmacokinetic studies,  
 
 Drug-drug interaction studies and  
 
 Toxicology studies.  
 
1.2. Estimation of drugs in dosage forms3 
The methods of estimation of drugs are divided into physical, chemical, and 
physico-chemical and biological ones. Among these physico-chemical and 
physical methods are widely used. Physical methods of analysis involve the study 
of the physical properties of a substance. They include determination of the 
solubility, transparency or degree of turbidity, color, density or specific gravity 
(for liquids), moisture content and melting, freezing and boiling points. Physico 
chemical methods are employed to study the physical phenomenon that occurs as a 
result of chemical reactions. 
 
Among the physicochemical methods the most important are optical 
(refractometry, polarometry, emission and the fluorescence methods of analysis, 
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photometry including photo colorimetry and spectrofluorimetry covering UV-
Visible and I.R. regions, Nephelometry and turbidimetry), Electro chemical 
(potentiometry, colorimetry, amperometry, and polarography) and 
chromatographic methods like 
 
(column,  paper,  thin  layer,  gas  liquid,  high  performance  liquid)  etc. 
 
Method involving nuclear reactions such as nuclear magnetic resonance 
 
(N.M.R) and paramagnetic resonance (P.M.R) are becoming more and more 
popular. The combination of liquid chromatography with mass spectroscopy is one 
of the most powerful tools available. 
 
The chemical methods include the gravimetric and volumetric procedures, 
which are based on complex formation, acid-base reactions, precipitations and red-
ox reactions, titration in non-aqueous media and complexometric titrations are 
various types which are widely used in pharmaceutical analysis. 
 
Analytical methods for the drugs in individual or combined dosage forms includes 
 
a. Classical separation or wet analysis (Non-instrumental)  
 
 
b. Instrumental  method of analysis  
 
 Spectral methods  
 
 Electro analytical methods  
 
 Chromatographic methods  
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Classical separation or wet analysis (Non-instrumental) 
 
 
These processes subject the component of interest to classical separation 
techniques like extraction or isolation, then with a suitable estimation procedure 
namely gravimetry and volumetry etc. 
 
Instrumental method of analysis 
 
By this process, the component of interest is separated and or analysed by 
using the following techniques 
 
i. Spectral Methods 
 
 
The spectral techniques are used to measure electromagnetic radiation, 
which is either absorbed or emitted by the sample. E.g. UV-Visible spectroscopy, 
IR-spectroscopy, NMR & ESR-spectroscopy, flame photometry, flourimetry, 
atomic absorption spectroscopy and etc. 
 
ii. Electro Analytical Methods 
 
 
Electro analytical methods involve the measurement of current voltage or 
resistance as a property of concentration of the component in 
 
olution mixture, eg. Potentiometry, conductometry and amperometry etc. 
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iii. Chromatographic Methods 
 
 
Chromatography is a separation technique that is based on differing 
affinities of a mixture of solutes between at least two phases. The result is a 
physical separation of the mixture into its various components. The affinities or 
interactions can be classified in terms of a solute adhering to the surface of a polar 
solid (adsorption), a solute dissolving in a liquid (partition), and a solute passing 
through or impeded by a porous substance based on its molecular size (exclusion). 
 
1.3. HPLC 
 
 
The High Pressure or Performance Liquid Chromatography (HPLC) is a 
type of chromatography in which separation occurs between a pressurised liquid 
as mobile phase and a stationary phase contained in a column, one end of which is 
attached to source of pressure.5,6 
 
The technique of High Performance Liquid Chromatography is so called 
because of its improvement performance when compared to classical column 
chromatography. It is also called as High pressure liquid chromatography since 
high pressure is used when compared to classical column chromatography. 
te of distribution of drugs between stationary and mobile phase is 
controlled by diffusion process, if diffusion is minimized, a faster and effective 
separation can be achieved. 
With HPLC, a pump (rather than gravity) provides the higher pressure 
required to propel the mobile phase and analyte through the densely packed 
column. The increased density arises from smaller particle sizes. This allows for a 
better separation on columns of shorter length when compared to ordinary column 
chromatography. 
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A liquid chromatography7 consists of a reservoir containing the mobile 
phase, a pump to force the mobile phase through the system at high pressure, an 
injector to introduce the sample in to mobile phase, a chromatographic column, a 
detector, and a data collection device such as computer, integrator or recorder. 
Short, small-bore columns containing densely packed particles of stationary phase 
provide for rapid exchange of compounds between the mobile phase and 
stationary phases. In addition to receiving and reporting detector output, 
computers are used to control chromatographic settings and operations. 
 
1.4. Principle of separation8 
 
The principle of separation in normal phase mode and reverse phase mode 
is adsorption. When a mixture of components are introduced into a HPLC 
column, they travel according to their relative affinities towards the stationary 
phase. The component which has more affinity towards the stationary phase 
travels slower. The component which has less affinity towards the stationary phase 
travels faster. Since no two components have the same affinity towards the 
stationary phase,the components are separated. 
 
 
1.5. Types of HPLC techniques  
 
 
i) Based on modes of chromatography  
 
(a) Normal Phase chromatography  
 
(b) Reverse Phase chromatography  
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ii) Based on principle of separation  
 
(a) Adsorption chromatography  
 
(b) Ion exchange chromatography  
 
(c) Ion pair chromatography  
 
(d) Size exclusion chromatography  
 
(e) Affinity chromatography  
 
(f) Chiral phase chromatography  
 
iii) Based on elution technique  
 
(a) Isocratic separation  
 
(b) Gradient separation  
 
iv) Based on the scale of operation  
 
(a) Analytical HPLC  
 
(b) Preparative HPLC  
 
v) Based on the type of analysis  
 
(a) Qualitative analysis  
 
(b) Quantitative analysis  
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i) Based on Mode of Chromatography 
 
a) Normal phase mode chromatography 
 
In normal phase mode, the stationary phase (e.g. silica gel) is polar in 
nature and the mobile phase is non-polar. In this technique, non-polar compounds 
travel faster and are eluted first. This is because less affinity between solute and 
stationary phase. Polar compounds are retained for longer time in the column 
because more affinity towards stationary phase and takes more time to be eluted 
from the column. 
 
This is not advantageous in pharmaceutical applications since most of the 
drug molecules are polar in nature and takes longer time to be eluted and detected. 
Hence this technique is not widely used in pharmacy. 
 
b) Reverse phase mode chromatography 
 
 
In reverse phase technique, a non-polar stationary phase is used. The 
mobile phase is polar in nature. Hence polar components get eluted first and non-
polar compounds are retained for a longer time. Since most of the drugs and 
pharmaceuticals are polar in nature, they are not retained for a longer time and 
eluted faster, which is advantageous. Different columns are used are ODS 
(Octadecylsilane) or C18, C8, C4, etc. 
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1.2. LITERATURE REVIEW  
 
1.3. Literature review of drug  
 
 
Literature survey was carried out to enumerate the reported analytical 
methods for the selected drugs in individually or combination with other drugs. 
 
 Mahmood Ahmad et al.,12 validated and reported a rapid, sensitive and 
reproducible high performance liquid  
 
chromatographic (HPLC) method in plasma for simultaneous 
quantification of 5-fluorouracil, Adriamycin and  
 
Cyclophosphamide (FAC) using C18 column with mobile phase 
consisting of 0.05 M disodium hydrogen phosphate and acetonitrile 
(65:35 v/v) containing 0.5 mL/L triethylamine (pH 3.7).The flow rate 
was 0.650 mL/min. UV detection of FAC was set at 266, 254 and 198 
nm respectively. Total run time was 15 min and retention times for 5-
fluorouracil, cyclophosphamide and adriamycin were 4.1, 7.7 and 10.9 
min respectively.  
 
 Isarita Martins et al.,13 reported Simultaneous determination of 
Cyclophosphamide and Ifosfamide in Plasma using SPE-  
 
HPLC-UV method. The assay was performed by HPLC-UV, with a C18 
column (5μm, 150 x 4 mm) and detection in 195 nm. The mobile phase 
was constituted by phosphate buffer 10 mM pH 6.0 : acetonitrile (77.25 : 
22.75), with a flow of 1mL/min.  
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 Rodney R. Larson et al.,14 reported HPLC Method development for 
simultaneous analysis of five antineoplastic agents using  
 
Waters Symmetry C8  column with mobile phase consisting of  
 
22.75 percent acetonitrile in water buffered to a pH of 6.0. The detection 
was performed by UV detector at 195nm.  
 
 Abu M. Rustum et al.,15 had developed a RP-HPLC method for the 
determination of Cyclophosphamide in blood and plasma  
 
using a short column packed with 5-μm reversed-phase octadecylsilane 
(ODS) with an isocratic elution of 5 mM potassium phosphate (pH 6.80) 
& acetonitrile in the ratio 80:20 v/v at a flow-rate of 1.0 ml/min. The 
detection was performed by UV detector at 195nm.  
 
 Terry T. Kensler et al.,16 reported High-performance liquid 
chromatographic analysis of cyclophosphamide in the presence  
 
of its hydrolysis products. The drug was quantified using a UV detector 
at a low wavelength. A single band was observed for the intact drug, 
which was well separated from its hydrolysis product(s).  
 
 Nagulu Malothu et al.,17 developed and reported a rapid and simple 
HPLC method for the determination of cyclophosphamide  
 
in human serum using 250×4.6 mm ODS column with mobile phase 
consisting of water and acetonitrile (70:30) at a flow rate of 1.2ml/min. 
Para aminoacetophenone was used as internal  
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standard.  The  detection  was  performed  by  UV  detector  at 
 
197nm. 
 
 LI Su-hua et al.,18 reported HPLC method development for determining 
the concentration of Cyclophosphamide in the  
 
plasma of mice using diamonsil C18 column, with the detective UV 
wavelength of 200nm.Acetonitrile and water with the ratio of 18 : 82 
(V/V) was used as mobile phase at a flow rate of 0.5ml/min.  
 
 Respaud.R et al.,19 reported Fast Analysis of Chemotherapy Drugs with 
the Agilent Pursuit XRs Ultra Diphenyl Column.  
 
Using an HPLC system with Agilent Polaris and Agilent Pursuit 
columns, researchers at the Hôpital Européen Georges  
 
Pompidou validated a method that differentiated cancer drugs in less 
than three minutes. This is a major step in developing an analytical 
verification procedure to improve the quality of drug delivery for cancer 
patients, without compromising patient experience.  
 
 Zhuorong Li et al.,20  reported  Nitrobenzo-cyclophosphamides  
 
As potential  prodrugs  for  bioreductive activation using 
Eschericia   coli   nitroreductase.   Series   of   four benzo 
cyclophosphamide analogues were designed and 
 
synthesized incorporating a strategically placed nitro group in a position 
para to the benzylic carbon for reductive activation. 
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2.2. DRUG PROFILE 
 
2.2.1. CYCLOPHOSPHAMIDE (CP)46 
 
Description 
 
Cyclophosphamide is a synthetic alkylating agent chemically related to 
the nitrogen mustards with antineoplastic and immunosuppressive 
activities. It is a prodrug that requires activation by the cytochrome 
P450 enzyme system to form its pharmacologically active metabolite 4-
hydroxyl cyclo-phosphamide. The metabolites are genotoxic due to their 
ability to cross-link DNA and thereby cause DNA damages. 
 
 
Chemical structure 
 
(2-[bis(2chloroethyl)amino]tetrahydro2H1,3,2oxazaphosphorine2oxide) 
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Generic name: Cyclophosphamide 50mg 
 
Brand name:  Cytoxan 50mg 
 
Preparations: Powder for intravenous injection: 100, 200, 500, 1000, 
 
and 2000 mg.  Tablets: 25, 50 mg. 
 
Physical and chemical properties 
 
Basic physical and chemical properties of CP are summarized below 
 
Molecular formula: C7H15Cl2N2O2P 
 
Molecular weight: 261.09 
 
Physical properties:   Odourless, fine white crystalline powder 
 
Melting point: 49.5 – 53 ° C 
 
Boiling Point: 336° C 
 
Density: 1.479 g/cm3 
 
Solubility: sparingly soluble in water, methanol, 
 
Acetonitrile and slightly soluble in ethanol 
 
Partition coefficient:  0.63 
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pKa: 4.5-6.5 
 
Stability: Hydrolysis occurs at temperatures above 30 
 
°C, with removal of chlorine atoms. Sensitive 
 
to oxidation, moisture and light. 
 
 
 
Mechanism of action of CP 
 
First CP is converted by the liver into two chemicals acrolein and 
phosphoramide. Acrolein and phosphoramides are the active 
compounds that prevent cell division by cross linking DNA strands and 
decreasing DNA synthesis. 
 
 
Pharmacokinetics 
 
Absorption, distribution and elimination of CP 
 
CP is well absorbed orally, with peak concentrations occurring 
after 1-3 hours and has bioavailability of 85-100%. The drug is rapidly 
absorbed from the blood after IV injection. 
 
CP is distributed with a volume of distribution of 30-50 L, which 
approximates to the total body water. Penetration of CP and its 
metabolites into body fluids is limited. Metabolites like 
 
CarboxyCP and DicarboxyCP were not found in cerebrospinal fluid 
whereas PM and CP could be detected. 
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CP and its metabolites are eliminated by urine in 24 hours after 
the start of treatment. The major function of CP in the body is 
eliminated by hepatic metabolism, but small fraction is eliminated by 
renal excretion of unchanged drug in urine. 
 
Small fraction of CP dose is eliminated via faeces and expired air. The 
elimination half-life of CP ranges between 5-9 hours over a large 
concentration range. The plasma half-life of CP is approximately 5 h in 
human during the first day after the dose. 
 
Cyclophosphamide use 
 
CP has been widely in different disease treatments 
 
 ) Breast cancer  
 
a) Ovarian cancer  
 
b) Prostate cancer  
 
c) Lung cancer  
 
 Lupus erythematosus  
 
 Rheumatoid arthritis  
 
 Multiple Sclerosis  
 
 Idiopathic pulmonary fibrosis  
 
 Wegener granulomatosis  
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 Hodgkin’s Lymphoma  
 
 Thrombocytopenic purpura  
 
 Polyarteritisnodosa  
 
 Anaemia  
 
Side effects of Cyclophosphamide47 
 
It includes- 
 
 Hair loss  
 
 Vomiting  
 
 Diarrhoea  
 
 Mouth sores  
 
 Weight loss  
 
 Sterility  
 
 Jaundice  
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Adverse Effects48 
 
1.9.1. black, tarry stools  
 
1.9.2. red urine  
 
1.9.3. unusual bruising or bleeding  
 
1.9.4. unusual tiredness or weakness  
 
1.9.5. sore throat, cough, fever, or other signs of infection  
 
 swelling in the legs, ankles, or feet  
 
 chest pain  
 
Drug Interactions48 
 
 The rate of metabolism and the leukopenic activity of 
cyclophosphamide reportedly are increased by chronic administration of 
high doses of phenobarbital.  
 
 Cyclophosphamide treatment causes a marked and persistent inhibition 
of cholinesterase activity and potentiates the effect of succinylcholine 
chloride.  
 
 Allopurinol (Zyloprim) enhances the ability of cyclophosphamide to 
reduce production of blood cells from the bone marrow.  
 
 Increases the occurrence of heart failure that is caused by doxorubicin 
(Adriamycin),  
18 
 
 
 Increases  the  action  of  blood  thinners  such  as  warfarin  
 
(Coumadin),  and  decreases  the  effectiveness  of  quinolone  
 
antibiotics (Cipro). 
 
Dosage48 
 
 The usual initial dose of cytoxan for adults and children is  
 
40-50 mg/kg administered intravenously over 2-5 days in divided 
doses. This dose may repeated at 2-4 week intervals.  
 
 The usual oral dose is 1-5 mg/kg daily.  
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3.0. AIM AND OBJECTIVE 
 
The number of drugs and drug formulations introduced into the market 
has been increasing at an alarming rate. These drugs or formulations may be 
either new entities in the market or partial structural modifications of the 
existing drug or novel dosage forms. 
 
Most of the pharmaceutical industries rely upon quantitative chemical 
analysis to ensure that the raw material used and the final product thus obtained 
meets certain specifications and to determine how much of each component 
present in the final product. 
 
Standard analytical procedures for these drugs or formulations may not 
be available to develop newer analytical methods which are accurate, precise, 
specific, linear, simple and rapid. 
 
Moreover in the early part of the century only colorimetric and 
spectrophotometric methods were used for drug analysis due to reasons of 
economy and easy availability. These methods, however, are used to lesser 
extent today because they lack specificity, sensitivity and accuracy. The 
modern method of choice of assays is 
 
High – Pressure Liquid Chromatography (HPLC) which is a powerful and 
rugged method. It is also extremely precise, accurate, sensitive, specific, linear 
and rapid. 
 
The objective of the present research is to develop and validate a 
precise, accurate and robust method for the estimation of 
 
Cyclophosphamide from tablet dosage form and the extensive literature survey 
carried out revealed that several methods have been reported for simultaneous 
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estimation of Cyclophosphamide i.e., in combination with other drugs. 
However, there is no method reported for individual estimation in solid dosage 
form. 
 
 
3.0. PLAN OF WORK 
 
The plan of the work for the aimed study was designed as follows: 
 
1.4. Method development and optimization of chromatographic 
conditions  
 Selection of wavelength  
 
 Selection of initial separation conditions  
 
 Nature of the stationary phase  
 
 Nature of the mobile phase (pH, peak modifier, solvent strength, 
ratio and flow rate)  
 
 Sensitivity  
 
 
1.5. Validation of developed HPLC method (Acc. to ICH guidelines)  
 
The  method  developed  were  also  proposed  to  validate  using  the 
 
various validation performance parameters such as, 
 
 Selectivity/specificity  
 
 Linearity and range  
21 
 
 
 Accuracy  
 
 Precision (repeatability and reproducibility)  
 
 Limit of detection (LOD)/ Limit of quantification (LOQ)  
 
 Robustness  
 
 System suitability  
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1.0. MATERIALS REQUIRED  
 
1.1. Instruments used  
 
Table 1: Instruments Used During the Method Development 
 
S.No. Name Model Make Software  
      
1. Analytical Balance MS205DU Mettler Toledo -  
      
2. Micro Balance MX5 Mettler Toledo -  
      
3. pH Meter LP139SA POLMON -  
      
4. Centrifuge R-8CBL REMI 
-  
  
      
5. Ultra Sonicator 
- 
S V Scientific 
-  
   
      
6. Oven 
- 
S V Scientific 
-  
   
      
7. UV Lambda-25 Perkin Elmer UV Winlab  
 Spectrophotometer     
      
8. 
HPLC Agilent-1200 
Agilent 
Open lab  
 
control panel 
 
  
infinity series 
 
    
     
    E Z chrome  
      
9. UV-Visible / PDA PDA-1200 Agilent -  
 Detector infinity series    
      
10. Water Purifier MilliQ Millipore -  
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5.2. Chemicals used 
 
 
Table 2: Chemicals/Reagents Used During the Method Development 
 
S.NO. Name of the Make Grade 
 Chemical/Reagent   
    
1. Sodium Hydroxide SD fine chemicals Ltd AG 
    
2. Hydrochloric Acid SD fine chemicals Ltd AG 
    
3. Hydrogen Peroxide SD fine chemicals Ltd AG 
    
4. Acetonitrile Merck HPLC 
    
5. Water MilliQ HPLC 
    
6. Methanol Merck AG 
    
7. 0.45μm  Nylon Filter Millipore AG 
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For the determination of Cyclophosphamide in tablet dosage form by RP-
HPLC method the following Standard drug was used as a reference standard. 
 
S. No. Name Specification purity % Gift sample 
    
1 Cyclophosphamide 99.7 Celon Labs. 
    
 
 
 
For the determination of Cyclophosphamide in tablet dosage form by RP- 
 
HPLC method the following marketed formulation was used. 
 
 
Brand name Content Manufacturing company 
   
Cytoxan Cyclophosphamide(50mg) Celon Labs, India 
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1.6. EXPERIMENTAL INVESTIGATION  
 
 
1.7. Method development of cyclophosphamide  
 
 
A new RP-HPLC method was developed for the determination of 
Cyclophosphamide. The HPLC method was then validated to indicate that the 
analytical procedure used is suitable for intended use by using various 
parameters like specificity, linearity, accuracy, precision, robustness, and 
system suitability. 
 
6.1.1. Selection of Initial Conditions for Method Development 
 
 
a. Determination of Solubility of Drug 
 
Table 3: Solubility Analysis of drug. 
 
Solvent Solubility 
  
Water  
  
Methanol Sparingly soluble 
  
Acetonitrile  
  
Ethanol Slightly soluble 
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b. Determination of Absorption Maxima by PDA detector 
Preparation of Diluent 
 
Water: Acetonitrile (50:50) 
 
Procedure 
 
Accurately weighed   and   transferred   about   50   mg   of 
 
Cyclophosphamide into a 50 ml volumetric flask, added to it about 75 ml of 
diluent and sonicated to dissolve and diluted up to the mark with diluent and 
mixed well. Further diluted 5 ml of the above solution to 50 ml with diluent 
and mixed. (Concentration of Cyclophosphamide is about 0.1mg/ml). The PDA 
spectrum was shown in figure 2. 
 
c. Choice of instrument: High performance liquid chromatography. 
 
Preparation of Cyclophosphamide stock solution 
 
 
50mg of Cyclophosphamide was weighed and taken into clean 50mL 
dry volumetric flask and added small quantity of diluent for solubilising the 
drug and sonicated for about 10min and finally make up the solution with 
diluent. 
 
Preparation of working solution 
 
 
Form the stock solution transferred 5 ml of the solution into a clean and 
dry 50mL volumetric flask and added small quantity of diluent and sonicated 
for about 10min and finally made up the volume with diluent. 
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6.1.2 Method development trials 
 
 
Trail-1 
 
 
Mobile phase preparation 
 
The mobile phase was prepared by mixing water and acetonitrile in the 
ratio of 50:50. Then it was filtered and degassed. 
 
Chromatographic conditions 
 
Standard solution of Cyclophosphamide was loaded in the vial, injected 
and run for 15min. The HPLC parameters were set in the 
 
method as follows. The trial plot was shown in figure 3. 
 
 Column :  C18 100×4.6mm; 3.5µm 
 Column temperature  :  250C  
 Flow rate : 0.5mL/min 
 Injection volume : 20µL 
 Wave length : 195nm 
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Trail-2 
 
Mobile phase preparation 
 
 
The mobile phase was prepared by mixing water and acetonitrile in the 
ratio of 60:40. Then it was filtered and degassed. The trial plot was shown in 
figure 4. 
 
Chromatographic conditions 
 
 
 :  C18 100×4.6mm; 3.5µm 
 
 Column temperature  :  250C  
 
 Flow rate : 0.5mL/min 
 Injection volume : 20µL 
 Wave length : 195nm 
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Trail-3\\\ 
 
 
Mobile phase preparation 
 
 
The mobile phase was prepared by mixing water and acetonitrile in the ratio of 
75:35. Then it was filtered and degassed. The trial plot was shown in figure 5. 
 
Chromatographic conditions 
 
 
 :  C18 100×4.6mm; 3.5µm 
 
 Column temperature  :  250C  
 
 Flow rate : 0.5mL/min 
 Injection volume : 20µL 
 Wave length : 195nm 
 
 
Conclusion: After trails it was concluded that the mobile phase which is 
suitable was Water: acetonitrile (70:30) and injection volume is 20 µL. 
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Trail-4 (Optimized) 
 
 
Preparation of mobile phase 
 
 
Mix water and Acetonitrile in ratio of 70:30 (v/v) and degas and filter 
through 0.45 micron membrane filter. 
 
Diluent: Mobile phase itself is taken as diluent. 
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Chromatographic conditions 
 
 
The HPLC parameters were set in the method as per table 4.The 
 
optimized plot was shown in figure 6 
 
Table 4: Chromatographic conditions 
 
Parameters Description 
  
Column Agilent Zorbax Eclipse plus 100 x 4.6mm;3.5µ. 
Column temperature 250C 
Mobile phase Water : Acetonitrile (70:30) 
Flow rate 0.5mL/min 
Auto Sampler temperature 250C 
Injection volume 20µL 
Detector wavelength 195nm 
Run time 15min 
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6.2 Analytical method validation 
 
 
Validation of an analytical method is a process to establish by laboratory 
studies that the performance characteristic of the method meets the requirements 
for the intended analytical application. Performance characteristics are 
expressed in terms of analytical parameters. The proposed method was validated 
according to ICH guidelines.6.2.1 Validation parameters 
 
 
i. Specificity/forced degradation studies 
 
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. 
 
Lack of specificity of an individual analytical procedure may be compensated by other 
supporting analytical procedures. 
 
Cyclophosphamide Identification: Solutions of standard and Sample were prepared as 
per test method and injected into the chromatographic system. The specificity plots were 
shown in figure 7 and 8. 
 
Acceptance criteria: Chromatogram of Standard and sample should be identical with 
near/same Retention time. 
 
Blank interference: A study to establish the interference, blank detection was 
conducted. Mobile phase was injected as per the test method. . The specificity plot was 
shown in figure 7. 
 
Acceptance criteria: Chromatogram of blank did not show any peak at the retention 
time of analyte peak. 
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Forced degradation studies 
 
 
Degradation studies were carried out as per ICH guidelines. The objective of the 
study was to find out the degradation products, which in turn help in the establishment of 
degradation pathways and the intrinsic stability of drug molecule. In order to check the 
selectivity  
 
 
the proposed method, degradation studies were carried out by using acidic, basic, 
oxidative, photo and thermal conditions. 
 
Intentional degradation was attempted to stress conditions of acidic (0.1N HCl), 
basic/alkali (0.1N NaOH), oxidative degradation 
 
(5%H2O2) and thermal treatment (heated at 800c) to evaluate the ability of the proposed 
method to separate cyclophosphamide from its degradation products. 
 
A. Acidic degradation 
 
 
Forced degradation in acidic media was performed by taking weighed powdered 
sample equivalent to 50mg, in to 50mL volumetric flask. 10mL of 0.1N Hcl was added 
and refluxed at 700C/30min. Then 10mL of 0.1N NaOH was added and volume was 
made up to mark with diluent. 5 to 50mL of further dilution was made to get 0.1mg/mL 
of cyclophosphamide and inject the sample. 
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B. Alkali degradation 
 
 
Forced degradation in alkali media was performed by taking weighed powdered 
sample equivalent to 50mg, in to 50mL volumetric flask. 10mL of 0.1N NaOH was 
added and refluxed at 700C/30min. Then 10mL of 0.1N Hcl was added and volume was 
made up to mark with diluent. 5 to 50mL of further dilution was made to get 0.1mg/mL 
of cyclophosphamide and inject the sample. 
 
 
C. Oxidative degradation 
 
 
Forced oxidative degradation was performed by taking weighed powdered sample 
equivalent to 50mg, in to 50mL volumetric flask. 10mL of 5% H2O2 was added and 
refluxed at 700C/30min. Then volume was made up to mark with diluent. 5 to 50mL of 
further dilution was made to get 0.1mg/mL of cyclophosphamide and inject the sample. 
 
D. Thermal Degradation 
 
 
Cyclophosphamide pure drug was exposed to a controlled temperature oven NMT 
80ºc for half an hr. At sampling time accurately weighed powdered sample equivalent to 
50mg, in to 50mL volumetric flask. Then volume was made up to mark with diluent. 5 to 
50mL of further dilution was made to get 0.1mg/mL of cyclophosphamide and inject the 
sample. 
 
 
 
 
ii. Linearity and Range 
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Preparation of solutions for linearity 
 
From the stock solution transferred 3.5ml, 4.0 ml, 4.5 ml, 5.0 ml, 5.5 ml, 6.0 ml, 
of Cyclophosphamide each into a series of 50 ml volumetric flasks and add a few ml of 
diluent and sonicated for 15 min and later volume was made up with diluent. The final 
concentrations for linearity of Cyclophosphamide were 70-120µg/mL. 
 
The obtained value is y= 20405x - 244.681, R2 =0.999. The results were shown in figures 
14-19 and tabulated in the table no: 7. 
 
iii. Accuracy 
 
 
Preparation of solutions for Accuracy 
 
From the stock solution transferred 4.0, 5.0 and 6.0 ml of solutions into 3 separate 
50 ml volumetric flasks and dilute each of the flasks to 50 ml with mobile phase to get the 
desired concentrations of 80, 100 &120 mcg/mL respectively.These solutions were 
injected in 3 replicates. The percentage recovery was calculated from the data obtained 
and the results were shown in figures 20-28 and tabulated in the table no: 8. 
 
iv. Precision 
 
The precision studies were studied using six replicate measurements at 
0.1mg/mL. Statistical evaluation revealed that relative standard deviation of drug at 
different concentration for six injections was less than 2.0. The results were mentioned in 
the table no-9.Intermediate precision was established for the same analytical samples of 
concentration 0.1mg/mL. The typical variation was included like interday analysis. 
Statistical evaluation revealed that relative standard deviation of drug at different 
concentration for six injections was less than 2.0. The results were mentioned in the table 
no-10. 
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v. Limit of detection 
 
50mg of cyclophosphamide was weighed and make up to 50mL with mobile 
phase. From the above solution different concentrations of solutions were prepared as 
stated above i.e like linearity and the solutions were run as per chromatographic 
conditions. Based on the standard deviation of response and slope the LOD value of drug 
was calculated. 
 
vi. Limit of quantification 
 
50mg of cyclophosphamide was weighed and make up to 50mL with mobile 
phase. From the above solution different concentrations of solutions were prepared as 
stated above i.e like linearity and the solutions were run as per chromatographic 
conditions. Based on the standard deviation of response and slope the LOQ value of drug 
was calculated. 
 
vii. Robustness 
 
The robustness of an analytical procedure was tested by measuring its capacity to 
remain unaffected by small, but deliberate variations in the method parameters and 
provides an indication of its reliability during the normal use. For this study flow, mobile-
phase composition, column parameters were changed. The results were shown in figures 
41-45 and tabulated in the table.no:11-13. 
 
viii. System Suitability 
 
50mg of cyclophosphamide was weighed and taken into clean volumetric flask 
and added small quantity of mobile phase for solubilising the drug and sonicated for 
about 10min and finally make up the solution with mobile phase Pipette out 5ml of 
above solution was transferred into 50ml volumetric flask and make up the volume with 
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mobile phase to obtain concentration of 0.1mg/mL. This Standard solution was injected 
and the system suitability parameters are calculated and tabulated in the table no: 14. 
 
 
6.3 Assay for Marketed formulation 
 
 
Preparation of standard solution 
 
 
50mg of cyclophosphamide was weighed and taken into clean volumetric flask 
and added small quantity of mobile phase for solubilising the drug and sonicated for 
about 10min and finally make up the solution with mobile phase Pipette out 5ml of above 
solution was transferred into 50ml volumetric flask and make up the volume with mobile 
phase to obtain concentration of 0.1mg/mL. 
 
Preparation of sample solution 
 
 
Cytoxan tablets; claimed to contain 50mg of Cyclophosphamide was used in 
analysis. A total of 5 tablets were accurately weighed and powdered in a mortar. An 
amount equivalent to 50mg of Cyclophosphamide was taken and dissolved in some 
amount of diluent and sonicated for 20mins and made upto 50ml in 
 
50ml volumetric flask. The solution was transferred through a Whatmann No.1 filter 
paper. Further 5ml of the above solution was pipetted out into a 50ml volumetric flask 
and the volume was made up to 50ml with diluent(mobile phase) to obtain a 
concentration of 0.1mg/mL. 
 
 
Procedure 
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The prepared standard and sample solutions were injected in the HPLC by setting 
the optimized chromatographic conditions. The peak areas of standard and sample were 
determined. These values are 
 
substituted in the following formula to get the percentage purity of the marketed 
formulation. The results were shown in figure 47 and tabulated in the table no: 15. 
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7.0. RESULTS AND DISCUSSION 
 
 
7.1. Results for method development trials 
 
Absorption maxima 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: PDA spectrum of Cyclophosphamide 
 
 
Trial no. 1 
 
 
 
 
 
 
 
Figure 3: HPLC chromatogram of trial 1 
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Discussion 
 
Peak was eluted early & Some Placebo peaks were appeared. so the 
 
 
mobile phase has been changed for next trail. 
 
Trial no.2 
 
 
 
 
 
 
 
 
Figure 4: HPLC chromatogram of trial 2 
 
 
 
 
Discussion 
 
Placebo peaks were still appeared & Base line was not proper. so 
 
 
again gone for changing of mobile phase 
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Trial no. 3 
 
 
 
 
 
 
 
Figure 5: HPLC chromatogram of trial 3 
 
 
Discussion 
 
Placebo peaks were reduced but base line was not proper. so again 
 
 
gone for changing of mobile phase composition. 
 
 
 
 
Trial no.4 (Optimized) 
 
 
 
 
 
 
 
Figure 6: HPLC chromatogram of trial 4 
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Peak 
 
 
Cyclophosphami
de 
Retention 
Time 
 
 
5.600 
Area
 Area
% 
 
 
2050439 
100.00 
Theoretica
l 
plates(USP
) 
 
10385 
Asymmetr
y 
 
 
1.11 
 
 
Discussion 
 
The separation of analyte peak was achieved with good system 
suitability parameters. So these conditions are optimized for 
chromatographic run. 
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7.2. Results for method development 
 
The optimized chromatographic conditions for the method 
development and validation of Cyclophosphamide is as follows 
 
Optimized chromatographic conditions of Cyclophosphamide 
 
 
 
Parameters 
 
Description 
 
Column 
 
Column temperature 
 
Mobile phase 
 
Flow rate 
 
Sample temperature 
 
 
Agilent Zorbax Eclipse plus 100 x 4.6mm;3.5µ. 
 
250C 
 
Water : Acetonitrile (70:30) 
 
0.5mL/min 
 
25ºC 
 
 
 
Discussion 
 
The RP-HPLC method for Cyclophosphamide was optimized with the 
mobile phase consisting of Water & Acetonitrile (70:30). The detection 
was carried out at wavelength 195nm with a retention time of 5.6 min 
and peak asymmetry is 1.11. 
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7.3. Results for Analytical method validation 
 
 
Validation of an analytical method is process to establish that 
 
 
the performance characteristics of the developed method meet the 
 
 
requirements of the intended analytical application. Typical analytical 
 
 
parameters used in assay validation are: 
 
 
a) Specificity 
 
 
b) Linearity and Range 
 
 
c) Accuracy 
 
 
d) Precision 
 
 
Repeatability 
 
 
Intermediate precision 
 
 
e) Limit of Detection (LOD) 
 
 
f) Limit of Quantification (LOQ) 
 
 
g) Robustness 
 
 
h) System suitability 
 
 
45 
 
 
 
a) SPECIFICITY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 : HPLC Chromatogram of blank 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 : HPLC chromatogram of standard 
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Peak results 
 
 
 
Peak 
 
 
Cyclophosphamide 
 Retention Time 
 
5.587 
 
Area 
 
2039272 
 
Area% 
 
100.00 
 
Theoretical plates 
(USP) 
 
10383 
 
Asymmetry 
 
1.12 
 
 
 
 
Degradation Studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: HPLC chromatogram of acid degradation 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 : HPLC chromatogram of base degradation 
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Figure 11: HPLC chromatogram of heat degradation 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: HPLC chromatogram of peroxide degradation 
 
 
 
 
Table 6: Forced degradation results for Cyclophosphamide 
 
 
 
Mechanism of degradation 
 
Observation 
Acid(0.1NHCl 30min reflux) 
 
No interference at analyte peak 
 Base(1M NaOH 30 min reflux) 
 
No interference at analyte peak 
 
Heat at 500C for 1hr 
 
No interference at analyte peak 
 Peroxide(5% H2O2 30 min 
reflux) 
No interference at analyte peak 
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Discussion 
 
 
 
The HPLC chromatogram of blank does not contain any peaks, 
 
 
HPLC chromatogram of standard and sample containing 
 
 
Cyclophosphamide shows peaks at the same retention times. The HPLC 
 
 
chromatograms of degraded products show no interference at the analyte 
 
 
peaks. 
 
 
b) LINEARITY & RANGE 
 
The linearity of a method is its ability to obtain test results that 
 
 
are directly proportional to the sample concentration over a given range. 
 
 
The peak area and concentration were plotted to get a standard 
 
 
calibration curve. The correlation co-efficient and regression co-efficient 
 
 
were calculated. 
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Table 7: Linearity results of Cyclophosphamide 
 
 
 
Sl no 
 
Concentration 
 
mcg/ml. 
 
Area 
 
1 
 
70 
 
1427291 
 2 
 
80 
 
1627283 
 3 
 
90 
 
1840368 
 4 
 
100 
 
2048163 
 5 
 
110 
 
2239534 
 6 
 
120 
 
2447824 
 Slope 
 
20407.33 
 y-intercept 
 
-244.681 
 
R2 value 
 
0.999 
 
 
 
 
Linearity of Cyclophosphamide 
3000000 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
 
 2500000 
 
2000000 
 
1500000 
 
1000000 
 
500000 
 
y = 20405x R² = 0.999 
 
 
Area 
 
Linear (Area) 
 
 
0 50 100 150 
 
Concentration in µg/ml 
 
Figure 13: Linearity plot of Cyclophosphamide 
 
 
 
 
 
 
 
 
 
 
Figure 14: HPLC chromatogram of Cyclophosphamide linearity 70% 
 
 
Peak results 
 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 
Cyclophosphamide 5.579 1137297 9448 1.19 
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Figure 15: HPLC Chromatogram of Cyclophosphamide linearity 80% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 
Cyclophosphamide 5.580 1427283 10311 1.16 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: HPLC chromatogram of Cyclophosphamide linearity 90% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 
Cyclophosphamide 5.583 1740368 10362 1.11 
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Figure 17: HPLC chromatogram of Cyclophosphamide linearity 100% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 
Cyclophosphamide 5.587 2048163 10349 1.13 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: HPLC chromatogram of Cyclophosphamide linearity 110% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates (USP) 
Asymmetry 
 
Cyclophosphamide 
 
5.589 
 
2389534 
 
8926 
 
1.09 
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Figure 19: HPLC chromatogram of Cyclophosphamide linearity 120% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates (USP) 
 
Asymmetry 
 
Cyclophosphamide 
 
5.592 
 
2647825 
 
8982 
 
1.11 
 
 
 
Discussion 
 
Cyclophosphamide was found to be linear over the range of 70 to 
 
 
120µg/mL. R2 value for calibration plot of Cyclophosphamide was found 
 
 
to be 0.999 
 
 
c) ACCURACY 
 
The accuracy of a method is the closeness of the measured 
 
 
value to the true value for the sample. Accuracy is usually determined 
 
 
by recovery studies. 
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Table 8: Accuracy results for Cyclophosphamide 
 
 
Spiked 
Level 
 
Peak 
Area 
 
Amount added 
(mcg/ml) 
 
Amount found 
(mcg/ml) 
 
% Mean 
recovery 80% Prep-1 
 
1457483 
 
80.4 
 
79.5 
 
98.88 
 80% Prep-2 
 
1469380 
 
80.6 
 
79.3 
 
98.38 
 80% Prep-3 
 
1465411 
 
80.2 
 
79.4 
 
99.00 
 100% Prep-1 
 
2035189 
 
99.6 
 
99.2 
 
99.68 
 100% Prep-2 
 
2045174 
 
99.8 
 
99.2 
 
99.39 
 100% Prep-3 
 
2053232 
 
99.6 
 
99.3 
 
99.69 
 120% Prep-1 
 
2654239 
 
120 
 
119.7 
 
99.75 
 120% Prep-2 
 
2665314 
 
119.8 
 
119.2 
 
99.49 
 
120% Prep-3 
 
2674119 
 
120 
 
119.3 
 
99.41 
 Mean 
 
99.30 
 Standard deviation 
 
0.46 
 %RSD 
 
0.46 
 
 
 
 
 
 
 
 
 
 
Figure 20: HPLC chromatogram of Cyclophosphamide for accuracy 80% 
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Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.580 1457483 9730 1.15 
 
 
 
 
 
 
 
Figure 21: HPLC chromatogram of Cyclophosphamide for accuracy 80% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.573 1469380 9782 1.16 
 
 
 
 
 
 
 
Figure 22: HPLC chromatogram of Cyclophosphamide for accuracy 80% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.587 1465411 10457 1.13 
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Figure 23: HPLC chromatogram of Cyclophosphamide for accuracy 100% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamid 5.585 2035189 9761 1.17 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: HPLC chromatogram of Cyclophosphamide for accuracy 100% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.583 2045174 9893 1.13 
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Figure 25: HPLC chromatogram of Cyclophosphamide for accuracy 100% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.587 2053232 9950 1.14 
 
 
 
 
 
 
 
Figure 26: HPLC chromatogram of Cyclophosphamide for accuracy 120% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.593 2654239 9783 1.18 
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Figure 27: HPLC chromatogram of Cyclophosphamide for accuracy 120% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.600 2665314 9604 1.16 
 
 
 
 
 
 
 
 
Figure 28: HPLC chromatogram of Cyclophosphamide for accuracy 120% 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.607 2674119 9542 1.15 
 
Discussion 
 
The percentage recovery of Cyclophosphamide was found to be 
98.75%, 99.58% and 99.55% for accuracy 80%, 100% and 120% 
samples respectively. The %RSD of the samples was found to be less 
than 2. 
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d) PRECISION 
 
Repeatability 
 
The Repeatability studies were studied by six replicate 
measurements at 0.1mg/mL for Cyclophosphamide 
 
Table 9: Precision results of Cyclophosphamide 
 
 
Drug Conc. S.No Area 
 
 
 
 
 
0.1mg/mL 
 
Inj-1 2045164 
Inj-2 2044425 
Inj-3 2042132 
Inj-4 2053214 
Inj-5 2048155 
Inj-6 2051452 
Average 2047424 
STDEV 4298.60 
RSD 0.21 
 
 
 
 
Discussion: The % RSD value indicates a good degree of precision 
within the specified range. 
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Figure 29: HPLC chromatogram of Cyclophosphamide for repeatability 
 
(inj-1) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.587 2045164 9975 1.18 
 
 
 
 
 
 
 
 
 
 
Figure 30: HPLC chromatogram of Cyclophosphamide for 
repeatability (inj-2) 
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Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.585 2044425 9866 1.16 
 
 
 
 
 
 
 
 
 
Figure 31: HPLC chromatogram of Cyclophosphamide for 
repeatability (inj-3) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.584 2042132 9829 1.12 
 
 
 
 
 
 
 
 
 
 
Figure 32: HPLC chromatogram of Cyclophosphamide for 
repeatability (inj-4) 
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Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.580 2053214 9587 1.13 
 
 
 
 
 
 
 
 
 
 
Figure 33: HPLC chromatogram of Cyclophosphamide for 
repeatability (inj-5) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.583 2048155 9615 1.18 
 
 
 
 
 
 
 
 
Figure 34: HPLC chromatogram of Cyclophosphamide for 
repeatability (inj-6) 
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Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.585 2051452 9645 1.17 
 
 
termediate precision 
 
The Intermediate precision studies were studied by six replicate 
measurements at 0.1mg/mL for Cyclophosphamide. 
 
Table 10: Intermediate Precision results of Cyclophosphamide. 
 
 
Drug Conc. S.No Area 
 
 
 
 
 
0.1mg/mL 
 
Inj-1 2056122 
Inj-2 2048131 
Inj-3 2045148 
Inj-4 2055172 
Inj-5 2058188 
Inj-6 2061102 
Average 2053977 
STDEV 6109.89 
RSD 0.29 
 
 
 
Discussion: The % RSD value indicates a good degree of precision 
within the specified range. 
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Figure 35: HPLC chromatogram of Cyclophosphamide for intermediate 
precision (inj-1) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.601 2056122 9029 1.15 
 
 
 
 
 
 
 
 
 
 
Figure 36: HPLC chromatogram of Cyclophosphamide for intermediate 
precision (inj-2) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.597 2048131 9231 1.17 
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Figure 37: HPLC chromatogram of Cyclophosphamide for intermediate 
precision (inj-3) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.598 2045148 9437 1.14 
 
 
 
 
 
 
 
 
 
Figure 38: HPLC chromatogram of Cyclophosphamide for intermediate 
precision (inj-4) 
 
Peak results 
                Peak 
 
 
Cyclophosphamide 
Retention Time 
 
 
5.593 
Area 
 
 
2055172 
Theoretical 
plates (USP) 
9520 
Asymmetry 
 
 
1.11 
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Figure 39: HPLC chromatogram of Cyclophosphamide for intermediate 
precision (inj-5) 
 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.595 2058188 9643 1.16 
 
 
 
 
 
 
 
 
 
Figure 40: HPLC chromatogram of Cyclophosphamide for intermediate 
precision (inj-6) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.596 2061102 9633 1.17 
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Discussion 
 
The %relative standard deviation of Cyclophosphamide for 
repeatability was found to be 0.21. 
 
The %relative standard deviation of Cyclophosphamide for 
intermediate precision was found to be 0.29. 
 
Hence the % RSD values indicate a good degree of precision 
within the specified range. 
 
 
e) LIMIT OF DETECTION 
 
LOD was calculated by using standard deviation and slope values 
obtained from calibration curve. 
 
Discussion 
 
The LOD value of Cyclophosphamide was found to be 0.131µg/mL. 
 
f) LIMIT OF QUANTIFICATION 
 
LOQ was calculated by using standard deviation and slope values 
obtained from calibration curve. 
 
Discussion 
The LOQ value of Cyclophosphamide was found to be 0.398µg/mL. 
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g) ROBUSTNESS 
 
To establish the robustness of the HPLC method employed for 
analysis of assay of Cyclophosphamide, the method was 
challenged for various parameters like effect of mobile phase flow, 
changes in mobile phase composition and change in column. The 
observations in different conditions are tabulated below: 
 
 
Table-11: Effect of mobile phase flow ( 20% of Actual flow) 
 
 Actual flow 
(0.5 ml/min) 
 
20% Less flow 
(0.4 ml/min) 
 
20% Excess flow 
(0.6 ml/min) 
 Retention time (min) 5.587 5.610 5.577 
Theoretical Plates 10383 9075 8878 
Tailing Factor 1.12 1.09 1.08 
 
 
Table-12: Effect of changes in mobile phase composition 
( 1% Organic solvent) 
 
 Actual 
MP 
 
1% Excess 
Organic solvent 
 
1% Less 
Organic solvent 
 Retention time (min) 5.587 5.450 5.610 
Theoretical Plates 10383 8917 6398 
Tailing Factor 1.12 1.14 1.15 
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Table-13: Column to column variation 
 
 
 LCC11-003 LCC11-002 
Retention time (min) 5.587 5.595 
Theoretical Plates 10383 9523 
Tailing Factor 1.12 1.05 
 
 
 
 
 
 
 
 
 
 
Figure 41: HPLC chromatogram of Cyclophosphamide for robustness (flow 
1) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.610 2078518 9075 1.09 
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Figure 42: HPLC chromatogram of Cyclophosphamide for robustness (flow 
2) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.577 2066717 8878 1.08 
 
 
 
 
 
 
 
 
 
Figure 43: HPLC chromatogram of Cyclophosphamide for robustness 
(1% excess organic solvent) 
 
Peak results 
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Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamid 5.450 2076737 8917 1.14 
 
 
 
 
 
 
 
 
 
Figure 44: HPLC chromatogram of Cyclophosphamide for robustness 
(1% less organic solvent) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.610 2008119 6398 1.15 
 
 
 
 
 
 
 
 
 
Figure 45: HPLC chromatogram of Cyclophosphamide for robustness 
(Different column) 
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Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.595 2055288 9523 1.05 
 
 
Discussion: 
 
The robustness was tested by changing the flow rate, Mobile 
phase composition and column. And it was found that the system 
suitability parameters were within the acceptance criteria. 
 
 
h) SYSTEM SUITABILITY 
 
Table 14: system suitability data of Cyclophosphamide 
 
S.no. 
 
System Suitability 
Parameter 
Observations 
 
Proposed Acceptance 
Criteria 
1. 
 
% RSD for Five 
replicate injections of 
analyte peak in 
 
 
0.2 
 
Should be not more 
than 2.0% 
2. 
 
Tailing factor for 
analyte peak in 
standard solution 
 
1.11 
 
 
Should be not more 
than 2.0 3. 
 
Plate count for analyte 
peak in standard 
solution 
 
9176 
 
 
Should be not less than 
2000 
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Figure 46: HPLC chromatograms of Cyclophosphamide (system-
suitability) 
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Peak Results of Cyclophosphamide Standard 
 
 
S.NO 
 
Cyclophosphamide 
 Area 
 
Asymmetry 
 
Plate 
Count 1 
 
2050439 
 
1.11 
 
10383 
 
2 
 
2051086 
 
1.14 
 
10210 
 
3 
 
2051529 
 
1.17 
 
9848 
 
4 
 
2051650 
 
1.14 
 
9788 
 
5 
 
2051710 
 
1.15 
 
9785 
 Mean 
 
2051283 
 %RSD 
 
0.2 
 
  
 
Discussion 
 
The all system suitability parameters are within the acceptance 
criteria 
 
7.4. Assay for marketed formulation 
 
Peak results for Standard Solution of Cyclophosphamide (Assay-
Development) 
 
Cyclophosphamide 
S.No 
 
RT (min) 
 
Area 
 
Plate 
Count 
Tailing 
 
1 5.600 2050439 10383 1.11 
2 5.595 2051086 10210 1.14 
3 5.593 2051529 9848 1.17 
4 5.595 2051650 9788 1.14 
5 5.603 2051710 9785 1.15 
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Table 15: Peak results for Sample Solution of CP (Assay Development) 
 
S.no 
 
Tablet weight in mg 
 
105.5 
 
1 
 
Area(injection-1) 
 
2047489 
 2 
 
Area(injection-2) 
 
2048570 
 Average area 
 
2048029 
 
 Assay 
 
99.5 
 
 
 
 
 
 
 
 
 
 
Figure 47: HPLC Chromatograms for sample solutions (Assay-
Development) 
 
Peak results 
 
Peak 
 
Retention Time 
 
Area 
 
Theoretical 
plates 
Asymmetry 
 Cyclophosphamide 5.590 2047489 10264 1.14 
 
Discussion 
The percentage purity of Cyclophosphamide was found to be 
99.5. So this method was suitable for analysing the marketed 
formulations. 
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8.0. SUMMARY AND CONCLUSION 
 
 
 
8.1. SUMMARY 
 
 
Chapter 1 Opens with introduction giving a brief account of various 
 
 
aspects like chromatography, analytical method development 
 
 
and validation, 
 
 
Chapter 2 Explains about the drug profile of drug and literature review 
 
 
of various papers regarding about the drug. The 
 
 
chromatographic conditions from the papers were considered 
 
 
for developing new analytical method for 
 
 
Cyclophosphamideby RP-HPLC. 
 
 
Chapter 3 Explains the aim & objective of present investigation adopted 
 
 
for selected drugs. 
 
Chapter 4   Explains about the plan of the work. 
 
Chapter 5   Contains the materials used for the study 
 
Chapter 6      Containsexperimental investigation regarding theinformation 
 
about the chromatographic conditions of various method 
 
development trials and procedures for analytical method 
 
validation as per ICH guidelines. 
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Chapter 7    Consists of results obtained and the discussions about the results 
  indicating the acceptance of the results. Tables of the results obtained 
  for validation have been included below 
 
Chapter 8    Contains the summary of the research and conclusion. 
 
Chapter 9    Contains the references form which information of the titled 
  drugs and introduction of general methodology was collected 
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CONCLUSION 
 
The present research is to developed and validated a precise, accurate and 
robust method for the estimation of Cyclophosphamide from tablet dosage form and 
the extensive literature survey carried out revealed that several methods have been 
reported for simultaneous estimation of Cyclophosphamide i.e., in combination with 
other drugs. However, there is no method reported for individual estimation in solid 
dosage form. 
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